|
KMID : 0383820130750060256
|
|
Tuberculosis and Respiratory Diseases
2013 Volume.75 No. 6 p.256 ~ p.259
|
|
|
Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
|
|
Go Seong-Woo
Kim Boo-Kyeong
Lee Sung-Hak
Kim Tae-Jung
Huh Joo-Yeon
Lee Jong-Min
Hah Jick-Hwan
Kim Dong-Whi
Cho Min-Jung
Kim Tae-Wan
Kang Ji-Young
|
|
|
Abstract
|
|
|
|
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.
|
|
|
KEYWORD
|
|
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib, Lung Diseases, Interstitial
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|